Cite
HARVARD Citation
Rosa, D. et al. (2022). Cost-effectiveness of ribociclib for premenopausal or perimenopausal women with HR+/HER2− advanced breast cancer: a Brazilian public health care system perspective. Therapeutic advances in medical oncology. p. . [Online].